Portfolio Manager Factsheet

April 2017

Vertex, Illumina, and Alexion were the top positive contributors to performance during the month. Incyte shares underperformed due to the unexpected failure to obtain FDA approval of baricitinib by partner Eli Lilly.

Read more »

Register for email alerts

The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.